3 Reasons Bristol-Myers Squibb's Stock Could Rise

Bristol-Myers Squibb is on the cusp of moving into the next phase of its life cycle. Will this transformation propel shares higher?

Aug 22, 2014 at 4:47PM

The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb (NYSE:BMY) in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of other former top products.

Despite slumping sales for key drugs, Bristol-Myers had generated strong top-line growth through its lucrative diabetes collaboration with AstraZeneca (NYSE:AZN), which culminated in the co-purchase of Amylin Pharmaceuticals in 2012. Nevertheless, Bristol-Myers in December 2013 exited the diabetes market by selling its portion of the collaboration to AstraZeneca lock, stock, and barrel. 

The negative consequences of this business decision showed up in black and white on the company's recent second-quarter earnings report, which showed a 4% year-over-year drop in revenue. Bristol-Myers' share price has also fallen nearly 6% so far in 2014.

BMY Chart

BMY data by YCharts.

It's not all doom and gloom at Bristol-Myers, however. I believe there are three good reasons the company's stock is worth considering at current levels. But before diving into them, it's important to note that no one has a crystal ball -- we can't know what will happen to a stock's price due to all the unforeseen outside events that could occur.

Reason No. 1
Bristol-Myers should soon gain regulatory approvals for its experimental hepatitis C therapies in Europe and the U.S. While the hepatitis C market was widely expected to be strong heading into the approvals of new therapies from Gilead Sciences (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ), their commercial performance has blown away even the most optimistic projections. Gilead's Sovaldi posted $3.48 billion in second-quarter sales and J&J's Olysio soared into blockbuster status in the same time period with $725 million in sales.

Bristol-Myers' dual regimen of Daklinza and Sunvepra, indicated for hepatitis C genotype 1b patients, is scheduled for Food and Drug Administration review by Nov. 30. Daklinza, a potent NS5A inhibitor, is also under review with the FDA as a potential pan-genotype treatment when used in conjunction with other therapeutic agents. 

In June, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended Daklinza, meaning the drug could before year's end receive approval to be sold on the continent. Put simply, Bristol-Myers could become an important new player in the growing hepatitis C market in the near future.  

Reason No. 2
Bristol-Myers has made a concerted effort to become a major player in the field of oncology, especially immuno-oncology. Within the next 12 months, we should see the company gain two regulatory approvals for Opdivo, its much-heralded PD-1 immune checkpoint inhibitor.

Specifically, the company is filing regulatory applications for Opdivo as a potential treatment for advanced melanoma and non-small cell lung cancer. In another noteworthy move, Bristol-Myers also recently signed a research collaboration with Ono Pharmaceutical to bolster its roster of experimental immuno-oncology products. This is a huge potential market, and one investors should be watching keenly.

Reason No. 3
Although Bristol-Myers has been going through a tumultuous transformation over the past couple years, it has maintained a strong balance sheet and fundamental outlook. Per second-quarter earnings, the company reported having cash, cash equivalents, and marketable securities of $11.1 billion and a net cash position of $3.3 billion.

At present levels, Bristol-Myers' shares are therefore trading near a reasonable five times book value. Moreover, its strong balance sheet would allow the company to pursue potential acquisitions that could accelerate the transformation process. 

Foolish wrap-up
Bristol-Myers is such a large and diverse company that it's perhaps impossible to summarize all the reasons to be optimistic in a brief article. For instance, t
he recent label expansion of its blood thinner Eliquis, co-developed with Pfizer (NYSE:PFE), is yet another reason among many to believe that shares are presently undervalued. 

The Street has nonetheless maintained a neutral to bearish outlook on Bristol-Myers moving forward, projecting a comparatively high forward price-to-earnings ratio that tops 28.

My belief is that the Street isn't optimistic that Bristol-Myers will gain significant market share in the increasingly competitive hepatitis C market, and suspects Opdivo may have a tough time gaining approval because of its side effect profile. While these risks shouldn't be ignored, I think this top name in healthcare is close to breaking through into the next phase of its product life cycle, giving investors ample reason to dig deeper. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell owns shares of Johnson & Johnson. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers